Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
A treatment to prevent extreme symptoms and cut hospitalisation
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
If approved it will bring a second source of MMR vaccine to the US market
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Nearly 6,000 patients have been treated with the drug since 2017
Deal signed with AOP Orphan for US commercial rights
The drug is indicated for mild and transient episodes of heart block
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Subscribe To Our Newsletter & Stay Updated
